Tesamorelin

Tesamorelin is a potent synthetic GHRH analog - the most clinically validated peptide specifically for reducing visceral fat, the deep abdominal fat that wraps around internal organs. It is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy, a condition that causes abnormal fat accumulation, and is used off-label for visceral fat reduction in other populations. Its primary goal is fat loss, particularly stubborn belly fat. Secondary goals include modest muscle support, some cognition benefit, and general longevity support. It tends to be considered for patients where visceral fat is a meaningful health concern rather than purely aesthetic. Tesamorelin is given as a subcutaneous injection of 1-2 mg, taken daily before bed. A course typically runs three to six months before reassessment. The bedtime timing is consistent with the natural pattern of overnight GH secretion. The most clinically relevant caution is its effect on blood sugar - tesamorelin can affect glucose metabolism, and this is monitored at the time of consult and during the course. Like all GH secretagogues, it is contraindicated in anyone with a cancer history. It should not be combined with MK-677. It pairs well with ipamorelin and AOD-9604. In the US it is available as a compounded preparation outside the FDA-approved HIV lipodystrophy indication. Its evidence base is clinical - it has a meaningful body of human trial data behind it, which distinguishes it from emerging or anecdotal-only options. Your licensed provider in the PepDepo network will review your metabolic history and determine whether tesamorelin is appropriate and what monitoring is needed during your course.